Tenax Therapeutics, Inc. logo TENX - Tenax Therapeutics, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 5
HOLD 0
SELL 0
STRONG
SELL 0
| PRICE TARGET: $33.50 DETAILS
HIGH: $40.00
LOW: $27.00
MEDIAN: $33.50
CONSENSUS: $33.50
UPSIDE: 116.69%

Stock News

Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CHAPEL HILL, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced it awarded inducement option awards on July 1, 2026 as material inducements to the employment of three non-executive individuals newly hired by the Company in various accounting, clinical operations, and CMC/product development roles.

Jul 02, 2026 12:05 PM • globenewswire.com
Tenax Therapeutics Announces Late-Breaking Presentation of LEVEL Clinical Trial Data at ESC Congress 2026

Tenax Therapeutics Announces Late-Breaking Presentation of LEVEL Clinical Trial Data at ESC Congress 2026

Abstract recently submitted in anticipation of initial data analysis ahead of ESC Company expects to report topline LEVEL results in August CHAPEL HILL, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”) announced today that results from the Phase 3 LEVEL clinical trial will be presented in a Late-Breaking Clinical Science session at the European Society of Cardiology (ESC) Congress 2026, being held August 28-31 in Munich, Germany.

Jul 02, 2026 03:00 AM • globenewswire.com
Tenax Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Tenax Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

On track to report topline data from Phase 3 LEVEL study of TNX-103 in third quarter of 2026 Global Phase 3 LEVEL-2 clinical trial ongoing, enrollment completion anticipated by end of 2027 Strengthened leadership team with appointments of Thomas Staab as Chief Financial Officer and Timothy Healey, MBA, as Chief Commercial Officer CHAPEL HILL, N.C., May 12, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, reported today financial results for the quarter ended March 31, 2026 and provided an update on its recent corporate progress.

May 12, 2026 03:00 AM • globenewswire.com
Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CHAPEL HILL, N.C., May 08, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced it has awarded or will award inducement option awards between April 28, 2026 and June 1, 2026 as material inducements to the employment of four non-executive individuals newly hired by the Company in various clinical operations, medical, product development, and commercial roles.

May 08, 2026 12:05 PM • globenewswire.com
Tenax Therapeutics Appoints Thomas R. Staab, II as Chief Financial Officer

Tenax Therapeutics Appoints Thomas R. Staab, II as Chief Financial Officer

Mr. Staab has over 25 years of financial and executive experience across the healthcare industry CHAPEL HILL, N.C., April 22, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, announced today the appointment of Thomas R.

Apr 22, 2026 03:00 AM • globenewswire.com
Tenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Tenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Achieved randomization target of 230 patients in LEVEL study, topline data expected in third quarter of 2026 Initiated global Phase 3 LEVEL-2 clinical trial and opened long-term OLE study for patients to remain on drug CHAPEL HILL, N.C., March 10, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, reported today financial results for the year ended December 31, 2025 and provided an update on its recent corporate progress.

Mar 10, 2026 03:00 AM • globenewswire.com
Head-To-Head Contrast: Gyre Therapeutics (NASDAQ:GYRE) versus Tenax Therapeutics (NASDAQ:TENX)

Head-To-Head Contrast: Gyre Therapeutics (NASDAQ:GYRE) versus Tenax Therapeutics (NASDAQ:TENX)

Tenax Therapeutics (NASDAQ: TENX - Get Free Report) and Gyre Therapeutics (NASDAQ: GYRE - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, valuation, earnings and dividends. Analyst Recommendations This is a summary of

Mar 08, 2026 10:06 PM • defenseworld.net
Tenax Therapeutics to Participate in the 2026 Leerink Partners Global Healthcare Conference

Tenax Therapeutics to Participate in the 2026 Leerink Partners Global Healthcare Conference

CHAPEL HILL, N.C., March 03, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, announced today that the Company will participate in a fireside chat at the 2026 Leerink Partners Global Healthcare Conference, which is taking place from March 8-11, 2026, in Miami, FL.

Mar 03, 2026 02:00 AM • globenewswire.com
Tenax Therapeutics to Participate in the Guggenheim Emerging Outlook Biotech Summit 2026

Tenax Therapeutics to Participate in the Guggenheim Emerging Outlook Biotech Summit 2026

CHAPEL HILL, N.C., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, announced today that the Company will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026, which is taking place from February 11-12, 2026, in New York, NY.

Feb 04, 2026 02:00 AM • globenewswire.com

Price Targets